Skip to main content
. 2019 Jan;25(1):10.18553/jmcp.2019.25.1.080. doi: 10.18553/jmcp.2019.25.1.080

Table 3.

Probability of Being Cost-Effective at Different Cost-Effectiveness Thresholds

Effectiveness Thresholds
$50,000/QALY % $100,000/QALY % $150,000/QALY % $200,000/QALY % $250,000/QALY %
Versus cDMARD
 Sarilumab 0 0 1 26 68
 Adalimumab 0 0 0 2 20
Versus Adalimumab
 Sarilumab 100 100 100 100 100

cDMARD = conventional disease-modifying antirheumatic drug; QALY = quality-adjusted life-years.